Efficacy of once-weekly teriparatide for primary prevention of glucocorticoid-induced osteoporosis: A post hoc analysis of the TOWER-GO study.

Tanaka, Ikuko; Tanaka, Yoshiya; Soen, Satoshi; Oshima, Hisaji

Tanaka, Ikuko; Tanaka, Yoshiya; Soen, Satoshi; Oshima, Hisaji.

Affiliation

Tanaka I; Nagoya Rheumatology Clinic, Initiative for Rheumatology and Osteoporosis, Nagoya, Aichi, Japan.
Tanaka Y; The First Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Soen S; Soen Orthopedics, Osteoporosis, and Rheumatology Clinic, Kobe, Hyogo, Japan.
Oshima H; Graduate School of Nursing, Tokyo Healthcare University, Tokyo, Japan.

Mod Rheumatol ; 32(3): 634-640, 2022 Apr 18.

Article in En | MEDLINE | ID: mdl-34910192

Subject(s)

Bone Density Conservation Agents; Osteoporosis; Alendronate/therapeutic use; Bone Density; Bone Density Conservation Agents/adverse effects; Glucocorticoids/adverse effects; Humans; Osteoporosis/chemically induced; Osteoporosis/drug therapy; Osteoporosis/prevention & control; Primary Prevention; Teriparatide/therapeutic use

Key words

Bone mineral density; glucocorticoid-induced osteoporosis; once-weekly teriparatide; primary prevention

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Osteoporosis / Bone Density Conservation Agents Limits: Humans Language: En Journal: Mod Rheumatol Year: 2022 Document type: Article Affiliation country: Japan Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google